BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Akeso Secures NMPA Approval for Ebdarokimab in Moderate-to-Severe Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, ...

April 21, 2025 | News

WuXi Biologics Achieves Asia’s First Commercial PPQ Milestone with 3 x 5,000L Single-Use Bioreactors

- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,0...

April 21, 2025 | News

VelaVigo Bio Signs $440M Global Licensing Deal with Ollin Biosciences for First-in-Class Bispecific Antibody VBS-102

VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specif...

April 18, 2025 | News

Porton Advanced Supports IND Approval of Tasly’s Dual-Targeting CAR-T Therapy for Recurrent Glioblastoma

Porton Advanced proudly announces its CDMO support for Tasly Pharmaceutical Co., Ltd.'s innovative CAR-T therapy, "P134 Cell Injection," which has received...

April 17, 2025 | News

Fangzhou Launches AI-Driven Hepatitis Training Center with Guangdong Institute at Liver Disease Forum 2025

Fangzhou Inc., a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area Int...

April 17, 2025 | News

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

April 16, 2025 | News

Belief BioMed and Takeda China Announce NMPA Approval of China’s First Gene Therapy for Hemophilia B

Belief BioMed ("BBM") and Takeda China jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has be...

April 11, 2025 | News

Darnatein Secures First International Patent in China for AI-Engineered Osteoarthritis Drug Technology

Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international pat...

April 10, 2025 | News

RemeGen’s Telitacicept Shows Best-in-Class Efficacy in Phase 3 Trial for Generalized Myasthenia Gravis

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...

April 09, 2025 | News

China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the se...

April 08, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Peijia Medical and dsm-firmenich Forge Strategic Innovation Partnership to Advance Next-Gen Polymer Heart Valve Technologies

Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and d...

April 02, 2025 | News

Yingli Pharma Receives FDA Clearance to Launch Global Phase 3 Trial of Linperlisib for Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic...

April 02, 2025 | News

Merck Secures Global Rights to Abbisko’s Pimicotinib with $85M Option Exercise

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), w...

April 01, 2025 | News

Stay Connected